Computational drug discovery and design embodies the integration of advanced computational methods, machine learning, and cheminformatics to streamline the identification and optimisation of ...

Deep Origin, the computational drug discovery company replacing guesswork with prediction in small molecule drug development, today announced the promotion of Natalie Ma, PhD, to Chief Business ...

Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug molecule and the target being crucial for reducing drug discovery costs, ...

The collaboration builds on Biophytis' ongoing partnership with LynxKite and aligns with Singapore’s research, innovation and enterprise (RIE) 2030 plan.

PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to ...

You’ve discovered some interesting biology and have a set of required parameters, thousands of data points, a budget and a deadline. How can you harness the power of computational chemistry to reach ...

In what Lawrence Livermore National Lab said is “a substantial milestone for supercomputing-aided drug design,” LLNL and BridgeBio Oncology Therapeutics today announced clinical trials have begun for ...

Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...

Computational drug discovery and design integrates advanced computer‐aided methodologies with chemical and biological insights to accelerate the identification and optimisation of therapeutic agents.

Precise calculations of binding free energy are pivotal in reducing the high costs and inefficiencies of drug discovery. A recent study presents PairMap, an innovative computational tool that ...